News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,962 Results
Type
Article (42783)
Company Profile (286)
Press Release (686884)
Multimedia
Podcasts (81)
Webinars (20)
Section
Business (207805)
Career Advice (2061)
Deals (35912)
Drug Delivery (109)
Drug Development (81879)
Employer Resources (176)
FDA (16563)
Job Trends (15144)
News (350716)
Policy (33039)
Tag
Academia (2677)
Academic (1)
Accelerated approval (23)
Adcomms (24)
Allergies (123)
Alliances (50953)
ALS (159)
Alzheimer's disease (1641)
Antibody-drug conjugate (ADC) (263)
Approvals (16738)
Artificial intelligence (485)
Autoimmune disease (116)
Automation (33)
Bankruptcy (362)
Best Places to Work (11810)
BIOSECURE Act (20)
Biosimilars (175)
Biotechnology (188)
Bladder cancer (144)
Brain cancer (52)
Breast cancer (581)
Cancer (4409)
Cardiovascular disease (359)
Career advice (1740)
Career pathing (34)
CAR-T (263)
CDC (46)
Celiac Disease (1)
Cell therapy (695)
Cervical cancer (34)
Clinical research (69293)
Collaboration (1494)
Company closure (4)
Compensation (1036)
Complete response letters (46)
COVID-19 (2730)
CRISPR (84)
C-suite (697)
Cystic fibrosis (135)
Data (5672)
Decentralized trials (2)
Denatured (29)
Depression (115)
Diabetes (453)
Diagnostics (6802)
Digital health (40)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (218)
Drug pricing (166)
Drug shortages (28)
Duchenne muscular dystrophy (210)
Earnings (90249)
Editorial (51)
Employer branding (21)
Employer resources (152)
Events (118221)
Executive appointments (961)
FDA (19301)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1343)
Gene editing (184)
Generative AI (41)
Gene therapy (540)
GLP-1 (919)
Government (4684)
Grass and pollen (6)
Guidances (375)
Healthcare (19201)
HIV (48)
Huntington's disease (40)
IgA nephropathy (75)
Immunology and inflammation (230)
Immuno-oncology (35)
Indications (75)
Infectious disease (2974)
Inflammatory bowel disease (179)
Inflation Reduction Act (13)
Influenza (101)
Intellectual property (212)
Interviews (321)
IPO (16726)
IRA (48)
Job creations (3686)
Job search strategy (1460)
Kidney cancer (15)
Labor market (80)
Layoffs (547)
Leadership (29)
Legal (7982)
Liver cancer (88)
Longevity (13)
Lung cancer (609)
Lymphoma (348)
Machine learning (38)
Management (60)
Manufacturing (679)
MASH (153)
Medical device (13921)
Medtech (13958)
Mergers & acquisitions (20158)
Metabolic disorders (1138)
Multiple sclerosis (145)
NASH (16)
Neurodegenerative disease (280)
Neuropsychiatric disorders (71)
Neuroscience (2730)
NextGen: Class of 2025 (6674)
Non-profit (4613)
Now hiring (60)
Obesity (527)
Opinion (253)
Ovarian cancer (150)
Pain (170)
Pancreatic cancer (190)
Parkinson's disease (254)
Partnered (31)
Patents (450)
Patient recruitment (388)
Peanut (54)
People (59613)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21637)
Phase II (30498)
Phase III (22713)
Pipeline (3748)
Policy (263)
Postmarket research (2578)
Preclinical (9320)
Press Release (68)
Prostate cancer (215)
Psychedelics (42)
Radiopharmaceuticals (269)
Rare diseases (708)
Real estate (6073)
Recruiting (69)
Regulatory (24186)
Reports (52)
Research institute (2479)
Resumes & cover letters (355)
Rett syndrome (23)
RNA editing (12)
RSV (73)
Schizophrenia (135)
Series A (217)
Series B (169)
Service/supplier (11)
Sickle cell disease (93)
Special edition (20)
Spinal muscular atrophy (156)
Sponsored (41)
Startups (3681)
State (2)
Stomach cancer (16)
Supply chain (97)
Tariffs (81)
The Weekly (50)
Vaccines (952)
Venture capital (71)
Weight loss (342)
Women's health (74)
Worklife (18)
Date
Today (87)
Last 7 days (544)
Last 30 days (2309)
Last 365 days (30720)
2025 (29880)
2024 (35625)
2023 (40575)
2022 (51676)
2021 (56277)
2020 (54840)
2019 (47547)
2018 (35740)
2017 (32700)
2016 (32117)
2015 (38225)
2014 (31855)
2013 (27020)
2012 (29209)
2011 (29902)
2010 (27893)
Location
Africa (760)
Alabama (78)
Alaska (7)
Arizona (287)
Arkansas (13)
Asia (39986)
Australia (6525)
California (10439)
Canada (3090)
China (981)
Colorado (432)
Connecticut (447)
Delaware (310)
Europe (87060)
Florida (1540)
Georgia (332)
Hawaii (2)
Idaho (62)
Illinois (785)
India (57)
Indiana (492)
Iowa (21)
Japan (363)
Kansas (124)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1324)
Massachusetts (7532)
Michigan (304)
Minnesota (591)
Mississippi (5)
Missouri (119)
Montana (31)
Nebraska (26)
Nevada (115)
New Hampshire (74)
New Jersey (2814)
New Mexico (29)
New York (2780)
North Carolina (1370)
North Dakota (9)
Northern California (4991)
Ohio (312)
Oklahoma (21)
Oregon (39)
Pennsylvania (2133)
Puerto Rico (19)
Rhode Island (45)
South America (1135)
South Carolina (59)
South Dakota (1)
Southern California (4040)
Tennessee (164)
Texas (1623)
United States (37335)
Utah (312)
Vermont (1)
Virginia (240)
Washington D.C. (79)
Washington State (855)
West Virginia (4)
Wisconsin (92)
Wyoming (2)
729,962 Results for "integral molecular inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
Novartis and Monte Rosa first partnered in October 2024 for a molecular glue asset for immune-mediated and autoimmune diseases. This time, the pharma is putting $120 million down upfront for more of the biotech’s AI-discovered degraders.
September 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 million secured Rapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets
September 4, 2025
·
1 min read
Press Releases
Clinical Genomics Market Surges in 2025 with NABL-Accredited Molecular Labs and AI-Integrated Platforms
July 1, 2025
·
1 min read
Press Releases
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
December 10, 2025
·
5 min read
Press Releases
Study Establishes Molecular Link Between Tumor Metabolism and Drug Engagement in Cancer Cells
December 10, 2025
·
8 min read
Press Releases
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
November 10, 2025
·
2 min read
Press Releases
Arima Genomics Announces Data Presentation at the Association for Molecular Pathology 2025
November 14, 2025
·
2 min read
Press Releases
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry
November 20, 2025
·
3 min read
Press Releases
TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
December 3, 2025
·
3 min read
Business
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.
May 15, 2024
·
6 min read
1 of 72,997
Next
